This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at email@example.com or call 800-767-3771 ext. 9339.
Leading healthcare information technology (“HCIT”) solutions provider, Cerner Corporation ( CERN - Analyst Report ) recently reported that it was chosen by WellPoint Inc. (WLP), a large health benefits firm, to team up for a project to check for ICD-10 commercial continuity. Cerner will carry out complete ICD-10 and ICD-9 checks with WellPoint for chosen clients.
Cerner believes that its role in the project will permit it to test its composite systems before the transition to ICD-10. The transition may severely affect the sales of health care entities. The purpose of this project is to establish that work flows will function across all systems.
WellPoint is a standalone licensee of Blue Cross and Blue Shield Association. The company caters to over 36 million individuals through its affiliated plans and about 67 millions persons via its subsidiaries.
Cerner remains the trend setter among pure-play, publicly traded healthcare IT (HCIT) vendors. The company is diversified not only on a global basis but serves both hospitals and ambulatory outfits. Its integrated solutions have captured market share. While greenfield opportunities are shrinking, the replacement market is growing.
We believe long-term investors may consider Cerner, as it serves a sizeable installed hospital base that requires composite clinically-oriented applications complying with “meaningful use” requirements, reimbursement difficulties and complicated coding challenges. The company has long-standing, integrated and seamless solutions for both inpatient and ambulatory settings.
We currently have a Zacks Rank #3 (Hold) on Cerner. However, we are more positive about other stocks such as Merge Healthcare Incorporated ( MRGE - Analyst Report ) and Becton, Dickinson and Company ( BDX - Analyst Report ) both of which carry a Zacks Rank #2 (Buy) and are expected to do well.
Please login to Zacks.com or register to post a comment.